Bone marrow transplantation for chronic granulocytic leukemia

Thirty patients with chronic granulocytic leukemia (CGL), were given cyclophosphamde 60 mg/kg on each of 2 consecutive days, followed by total body irradiation (TBI) 10 Gy and an HLA‐identical bone marrow transplant (BMT). Eleven patients were in the accelerated phase of their disease (CGLacc) or in...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1986-11, Vol.58 (10), p.2307-2311
Main Authors: Bacigalupo, Andrea, Frassoni, Francesco, van Lint, Maria Teresa, Occhini, Domenico, Pittaluga, Pier Antonio, Repetto, Mario, Piaggio, Giovanna, Sessarego, M., Caimo, Attilio, Congiu, Angela, Marmont, Alberto
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antibodies, Monoclonal - therapeutic use
Biological and medical sciences
Bone Marrow Transplantation
Female
Graft vs Host Disease - etiology
Hematologic and hematopoietic diseases
Humans
Leukemia, Myeloid - surgery
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
T-Lymphocytes - immunology
Time Factors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thirty patients with chronic granulocytic leukemia (CGL), were given cyclophosphamde 60 mg/kg on each of 2 consecutive days, followed by total body irradiation (TBI) 10 Gy and an HLA‐identical bone marrow transplant (BMT). Eleven patients were in the accelerated phase of their disease (CGLacc) or in second/secondary chronic phase (CGL‐2CP), with a median age of 33 years: four patients died of transplant related complications, and four of recurrent leukemia; three patients are alive and well 19, 31, 33 months from BMT. The actuarial 33‐month survival is 27%. The actuarial relapse rate is 50%. Nineteen patients were in their first chronic phase (1CP), with a median age of 32 years: three died of graft versus host disease (GvHD), two of infection, and two of acute respiratory distress syndrome (ARDS); 12 are alive and well 6 to 29 months post‐BMT. The actuarial 29‐month survival is 63%. The actuarial survival of patients younger than 30 years is 63%, compared to 62% for patients older than 30 (P = 0.1). The survival of patients grafted within or after 24 months from the onset of CGL is respectively 87% and 45% (P = 0.04). None of the patients grafted in 1CP had a true hematologic‐cytogenetic relapse. The Ph′ chromosome was detected on one occasion in two patients 12, 13 months post‐BMT: they both remain hematologically normal and Ph1‐negative 3 to 6 months later, after discontinuation of cyclosporin A. This study confirms that survival exceeding 60% can be obtained in CGL in the first chronic phase, whereas less than 30% of patients will survive if grafted in accelerated, second/secondary chronic phase, mainly because of leukemic relapse. The duration of the disease seems to be relevant to the outcome of the transplant. The effect of post‐transplant immunosuppression, in our case cyclosporin A, on the interaction between normal and Ph1‐positive hemopoietic cells, may deserve further attention.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19861115)58:10<2307::AID-CNCR2820581025>3.0.CO;2-H